Other peptide vaccine studies have targeted major mutated genes involved with AML that induce T-cell responses, including Wilms’ tumor 1 (WT1), proteinase 3 (PR3), hyaluronic acid-mediated motility receptor (RHAMM), and mucinone1 protein (MUC1). The gene discussed is PRTN3; the disease is acute myeloid leukemia.